A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.

by Valentín García-Gutiérrez, María T Gómez-Casares, José M Puerta, Juan M Alonso-Domínguez, Santiago Osorio, Juan C Hernández-Boluda, Rosa Collado, María J Ramírez, Fátima Ibáñez, María L Martín, Juan D Rodríguez-Gambarte, Carolina Martínez-Laperche, Montse Gómez, Dolly V Fiallo, Sara Redondo, Alicia Rodríguez, Concepción Ruiz-Nuño, Juan L Steegmann, Antonio Jiménez-Velasco, Spanish Group of Chronic Myeloid Leukemia (GELMC)
Published 2017-01-01